• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Minerals
    Tech
    Life Science
    Life Science Market
    Life Science News
    Life Science Stocks
    • Life Science Market
    • Life Science News
    • Life Science Stocks
    life science investing

    FDA Drug Approvals Decline

    Investing News Network
    Jan. 06, 2014 11:11AM PST
    Life Science Investing

    CIO Today reported that the U.S. Food and Drug Administration approved 27 first-of-a-kind drugs in 2013, down from 39 new medications in 2012, which was a 15-year high.

    CIO Today reported that the U.S. Food and Drug Administration approved 27 first-of-a-kind drugs in 2013, down from 39 new medications in 2012, which was a 15-year high.
    As reported in the market news:

    Experts say the number of approvals declined mainly because there were fewer submitted. FDA drug approvals are watched closely by analysts as both a barometer of industry innovation and the government’s efficiency in reviewing new therapies.
    Despite the decline, FDA officials say the tally of innovative medications approved last year is in line with the historical trend. On average, the FDA has approved 28 first-of-a-kind drugs annually over the past five years. 

    Read the full story on CIO Today
     

    life science investing
    The Conversation (0)

    Go Deeper

    AI Powered
    Doctor using tablet with medical icons overlayed.

    Biotech and Pharma Market Update: Q3 2025 in Review

    Test tubes.

    Biotech Market Forecast: Top Trends for Biotech in 2025

    Latest News

    Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases

    Nextech3D.ai: Disrupting the Global Events Management Industry with AI and Blockchain

    Appendix 4C and Quarterly Activities Report - September 2025

    More News

    Outlook Reports world

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Life Science Investing Stocks

    Defence Therapeutics Class A

    DTC:CC

    Cloud DX

    CDX:CA

    BioHarvest Sciences

    BHSC:CNX

    Billy Goat Brands

    GOAT:CC

    Contakt World

    HELP:CNX
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES